Search
Dicyclomine
go.drugbank.com/drugs/DB00804ApprovedInvestigationalDicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder … [A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.
Mixtures: แอนพัส 520Products: RELESTAL PEDIATRIC SYRUP 10 mg/5 ml, Bentylol Inj 10mg/mlNadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigational[A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922] … Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.
Mixtures: CORGARETIC (NADOLOL/ BENDROFLUMETIAZIDA) 80/5 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesCelecoxib
go.drugbank.com/drugs/DB00482ApprovedInvestigational[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. … [A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesSynonyms: p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamideIpratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigational[A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol
Mixtures: İPRAVENT 20 MCG/100 MCG AEROSOL İNHALASYONU, SÜSPANSİYON (200 DOZ), COMBIVENT OLCULU DOZ INHALATORLU AEROSOL 10 MLCategories: Agents to Treat Airway DiseaseGriseofulvin
go.drugbank.com/drugs/DB00400ApprovedVet approvedGriseofulvin may be given by mouth in the treatment of tinea infections.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP3A InducersInternational brands: Grison-250Fluocortolone
go.drugbank.com/drugs/DB08971ApprovedWithdrawnFluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.
Mixtures: ULTRALAN POMAT, 10 GR, ULTRALAN POMAT, 20 GRCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersXylometazoline
go.drugbank.com/drugs/DB06694ApprovedXylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels. … [A228508] Xylometazoline is available in over-the-counter (OTC) nasal sprays or drops to temporarily relieve nasal congestion due to cold, hay fever or other respiratory allergies.
Mixtures: nasic - Nasenspray 10 mg/500 mg, XYLAZOL PEDİYATRİK 0,5 MG/ML + 50 MG/ML BURUN SPREYİ, ÇÖZELTİ, 10 MLProducts: OTRIVINE MENTOL 1 MG/ML DOZ AYARLI BURUN SPREYI, ÇÖZELTİ, 10 ML, ZOLIN % 0,1 10 ML SPREYInsulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalAs of 2015, insulin glargine was reformulated by Sanofi as the product Toujeo in an extra-concentrated form containing 300IU/mL (compared to 100IU/mL contained in Lantus). … Use of the higher concentrated Toujeo as compared to Lantus results in slightly different pharmacokinetics, with a later onset (up to 6 hours) and duration of action (up to 30 hours).
Mixtures: SOLİQUA SOLOSTAR 100 U/ML + 50 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEM, โซลิควา (100 ยูนิต/มิลลิลิตร + 50 ไมโครกรัม/มิลลิลิตร)Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type
Mixtures: VOKANAMET 50 MG/1000 MG FİLM KAPLI TABLET, 60 ADET, FILM-COATED TABLETS 150 MG / 1000 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDecitabine
go.drugbank.com/drugs/DB01262ApprovedInvestigational[A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. … Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.
Synonyms: 5-azadeoxycytidine, 5-aza-2'-deoxycytidineProducts: DACOGEN 50 MG IV KONSANTRE İNFÜZYONLUK ÇÖZELTİ İÇİN TOZ, DESİTAB 50 MG IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 1 ADET